ESMO 2025: Novel Combinations Are Changing Standards of Care in Bladder Cancer
ESMO 2025 bladder cancer highlights include results from KEYNOTE-905/EV-303, RC48-C016, and IMvigor011 studies.
Phase 3 data from multiple studies presented at the European Society for Medical Oncology (ESMO) Congress 2025 demonstrated that novel staging approaches along with new therapy combinations, such as enfortumab vedotin (EV) plus pembrolizumab and disitamab vedotin plus toripalimab improved survival outcomes in patients with bladder cancer.
Experts attending the conference suggested that these results may be practice-changing for this patient population.
The final survival analysis of the randomized, controlled BladderPath trial showed greater bladder cancer-specific survival (BCSS) in patients with muscle-invasive bladder cancer (MIBC) who underwent multiparametric magnetic resonance imaging (MRI) before transurethral resection of bladder tumor (TURBT).
Author's summary: Novel combinations improve bladder cancer outcomes.
More News
- Defense attorney objects to any further delay in Amber Spradlin trial - Mountain Top Media
- Pyjama Day raises over £420 for Totnes charity
- Queen’s announced as Lead Educational Partner for Young Enterprise NI's Company Programme
- Mating injuries lead scientists to identify female dinosaurs
- Watch: New Hampshire mountain known for 'world's worst weather' blasted with 103 mph wind gust caught on video
- Voaden on warpath to open Totnes banking hub
- Racial Health Disparities Could Widen As States Grapple With Trump Cuts, Experts Warn
- Jonathan Bailey is People's Sexiest Man Alive 2025... but is he the next Batman?!
- Jonathan Bailey is People's Sexiest Man Alive 2025... but is he the next Batman?!
- Inside Selling Sunset Star Bre Tiesi's Lawsuit